Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MYEOV (myeloma overexpressed (in a subset of t (11;14) positive multiple myelomas))

Written2011-10Jérôme Moreaux
INSERM U1040, institut de recherche en biotherapie, CHRU Saint Eloi, 80 Av Augustain Fliche, 34295 Montpellier CEDEX 5, France
This article is an update of :
2002-12Johannes WG Janssen
Janssen Institut fur Humangenetik Universitatsklinikum Heidelberg Im Neuenheimer Feld 328 D-69120 Heidelberg, Germany

(Note : for Links provided by Atlas : click)


HGNC Alias symbOCIM
HGNC Previous namemyeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)
LocusID (NCBI) 26579
Atlas_Id 395
Location 11q13.3  [Link to chromosome band 11q13]
Location_base_pair Starts at 69294155 and ends at 69297287 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping MYEOV.png]
Local_order 350 kb centromeric of cyclin D1.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
DUSP8 (11p15.5)::MYEOV (11q13.3)FBXO32 (8q24.13)::MYEOV (11q13.3)
Note Detected by application of the NIH/3T3 tumorigenicity assay. However MYEOV cDNA was not positive in NIH/3T3 assay.


Note The MYEOV gene was originally isolated by the application of the NIH/3T3 tumorigenicity assay with DNA from a gastric carcinoma. The chromosomal region 11q13 is frequently associated with genetic rearrangements in a large number of human malignancies, including B-cell malignancies and overexpression of MYEOV is frequently observed in breast tumors and oral, esophageal squamous cell carcinomas and multiple myeloma. The presence of functional domains such as RNP-1 (motif typical of RNA binding protein) and the studies of the short hydrophobic regions and of the C-terminal leucine/isoleucine tail showed that MYEOV might be directed to the membrane. MYEOV small interfering RNA (siRNA) decreased proliferation of gastric cancer cells, colon cancer cell lines and multiple myeloma cells in vitro.
Description 2 exons; 3,5 kb transcript represents unspliced mRNA.
Transcription Main transcript 2,8 kb (broad band because of alternative splice products); minor transcript 3,5 kb; coding sequence 313 or 255 amino acids. In normal tissues hardly any expression detectable. High expression in a subset of multiple myeloma cell lines with a t(11;14)(q13;q32) and in breast tumors and esophageal squamous cell carcinomas with or without 11q13 amplification.
Pseudogene No pseudogenes have been reported for MYEOV.


Description 313 or 255 amino acids; contains one RNP-1 motif and 6 regions that might function as a transmembrane domain. Leucine-rich stretch at C-terminal.
Expression 5' UTR inhibits efficient translation of the protein.
Localisation In endoplasmic reticulum and mitochondria.
Homology No known homology.

Implicated in

Disease Subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Cytogenetics MYEOV overexpression due to juxtaposition to the 5' enhancer or the most telomeric 3' enhancer of the immunoglobulin heavy chain (IgH).
Entity 11q13 amplification and/or overexpression
Disease Breast cancer; esophageal squamous cell carcinomas.
Prognosis MYEOV DNA amplification correlated with estrogen and progesterone receptor-positive cancer, invasive lobular carcinoma type and axillary nodal involvement. In contrast to Cyclin D1 amplification, no association with disease outcome could be found.
Entity Multiple myeloma
Prognosis In a cohort of 171 myeloma patients, patients with MYEOVabsent MMC have an increased event-free survival compared to patients with MYEOVpresent MMC, after high-dose therapy and stem cell transplantation and a trend for increased overall survival. In a Cox proportional hazard model, MYEOV expression in MMC is predictive for event-free survival for patients independently of International Staging System stage, t(4;14) translocation, albumin, or B2M serum levels. In a second independent cohort of 208 patients (LR-TT3, from the University of Arkansas for Medical Sciences (Little Rock, AR, USA)), MYEOV had a "present" call in MMCs of 73% of patients. Patients with MYEOVabsent MMCs had a significant better overall survival in the LR-TT3 cohort.
Oncogenesis In a cohort of 171 patients, MMC of 79% of the patients with newly diagnosed MM express MYEOV gene. A treatment with 5-aza-2'-deoxycytidine of 2 MYEOVabsent myeloma cell lines induced MYEOV expression without affecting that in the MYEOVpresent myeloma cells. MYEOV siRNA did not significantly induce apoptosis in myeloma cell lines, but it blocked the cell cycle entry into the S-phase.
Entity Colon cancer
Oncogenesis Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of colon cancer cell lines in vitro. Furthermore, in colon cancer, MYEOV stimulates colorectal cancer cell migration in vitro. MYEOV expression is enhanced by PGE2 treatment in colorectal cancer cells.
Entity Gastric cancer
Oncogenesis Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation and invasion of gastric cancer cells in vitro.
Entity Neuroblastoma
Oncogenesis MYEOV is a candidate gene target in neuroblastoma that was identified by chromosomal gain 11q13 through SNP analysis. MYEOV expression was analyzed in 55 neuroblastoma samples including 25 cell lines. MYEOV was shown to be upregulated in 11 out of 25 neuroblastoma cell lines and 7 out of 20 fresh tumors. Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of neuroblastoma cell line in vitro.
Entity Oral squamous cell carcinoma
Oncogenesis Gain of 11q13 was significantly associated with cervical lymph node metastasis in oral squamous cell carcinoma (54 patients included in the study). Copy number amplification of MYEOV is associated with cervical lymph node metastasis in oral squamous cell carcinoma. Lymph node metastasis is associated with a significant decrease of 5-years survival in oral squamous cell carcinoma.


MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas.
Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J.
J Hum Genet. 2002;47(9):460-4.
PMID 12202983
MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2.
Lawlor G, Doran PP, MacMathuna P, Murray DW.
J Exp Clin Cancer Res. 2010 Jun 22;29:81.
PMID 20569498
Net1 and Myeov: computationally identified mediators of gastric cancer.
Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P.
Br J Cancer. 2006 Apr 24;94(8):1204-12.
PMID 16552434
MYEOV is a prognostic factor in multiple myeloma.
Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, Klein B.
Exp Hematol. 2010 Dec;38(12):1189-1198.e3. Epub 2010 Sep 18.
PMID 20854874
ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion.
Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P.
Biochem Biophys Res Commun. 2006 Jun 23;345(1):216-21. Epub 2006 Apr 27.
PMID 16678123
Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma.
Sugahara K, Michikawa Y, Ishikawa K, Shoji Y, Iwakawa M, Shibahara T, Imai T.
Int J Oncol. 2011 Oct;39(4):761-9. doi: 10.3892/ijo.2011.1094. Epub 2011 Jun 22.
PMID 21701773
Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma.
Takita J, Chen Y, Okubo J, Sanada M, Adachi M, Ohki K, Nishimura R, Hanada R, Igarashi T, Hayashi Y, Ogawa S.
Cancer Sci. 2011 Sep;102(9):1645-50. doi: 10.1111/j.1349-7006.2011.01995.x. Epub 2011 Jul 3.
PMID 21624008


This paper should be referenced as such :
Moreaux, J
MYEOV (myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas))
Atlas Genet Cytogenet Oncol Haematol. 2012;16(3):205-207.
Free journal version : [ pdf ]   [ DOI ]
History of this paper:
Janssen, JWG. MYEOV myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)). Atlas Genet Cytogenet Oncol Haematol. 2003;7(1):22-23.

External links


HGNC (Hugo)MYEOV   7563
Atlas Explorer : (Salamanque)MYEOV
Entrez_Gene (NCBI)MYEOV    myeloma overexpressed
GeneCards (Weizmann)MYEOV
Ensembl hg19 (Hinxton)ENSG00000172927 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000172927 [Gene_View]  ENSG00000172927 [Sequence]  chr11:69294155-69297287 [Contig_View]  MYEOV [Vega]
ICGC DataPortalENSG00000172927
Genatlas (Paris)MYEOV
Genetics Home Reference (NIH)MYEOV
Genomic and cartography
GoldenPath hg38 (UCSC)MYEOV  -     chr11:69294155-69297287 +  11q13.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MYEOV  -     11q13.3   [Description]    (hg19-Feb_2009)
GoldenPathMYEOV - 11q13.3 [CytoView hg19]  MYEOV - 11q13.3 [CytoView hg38]
Genome Data Viewer NCBIMYEOV [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AJ223366 AJ223366 AK000473 AK026148 AK290121
RefSeq transcript (Entrez)NM_001293291 NM_001293294 NM_001293296 NM_001300923 NM_001300924 NM_138768
Consensus coding sequences : CCDS (NCBI)MYEOV
Gene Expression Viewer (FireBrowse)MYEOV [ Firebrowse - Broad ]
GenevisibleExpression of MYEOV in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)26579
GTEX Portal (Tissue expression)MYEOV
Human Protein AtlasENSG00000172927-MYEOV [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ96EZ4   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ96EZ4  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ96EZ4
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)MYEOV
AlphaFold pdb e-kbQ96EZ4   
Human Protein Atlas [tissue]ENSG00000172927-MYEOV [tissue]
Protein Interaction databases
IntAct (EBI)Q96EZ4
Ontologies - Pathways
Ontology : AmiGOprotein binding  
Ontology : EGO-EBIprotein binding  
Atlas of Cancer Signalling NetworkMYEOV
Wikipedia pathwaysMYEOV
Orthology - Evolution
GeneTree (enSembl)ENSG00000172927
Phylogenetic Trees/Animal Genes : TreeFamMYEOV
Homologs : HomoloGeneMYEOV
Homology/Alignments : Family Browser (UCSC)MYEOV
Gene fusions - Rearrangements
Fusion : QuiverMYEOV
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMYEOV [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MYEOV
Exome Variant ServerMYEOV
GNOMAD BrowserENSG00000172927
Varsome BrowserMYEOV
ACMGMYEOV variants
Genomic Variants (DGV)MYEOV [DGVbeta]
DECIPHERMYEOV [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisMYEOV 
ICGC Data PortalMYEOV 
TCGA Data PortalMYEOV 
Broad Tumor PortalMYEOV
OASIS PortalMYEOV [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMYEOV  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DMYEOV
Mutations and Diseases : HGMDMYEOV
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)MYEOV
DoCM (Curated mutations)MYEOV
CIViC (Clinical Interpretations of Variants in Cancer)MYEOV
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry MYEOV
NextProtQ96EZ4 [Medical]
Target ValidationMYEOV
Huge Navigator MYEOV [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDMYEOV
Pharm GKB GenePA31362
Clinical trialMYEOV
DataMed IndexMYEOV
PubMed26 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Jan 20 14:12:39 CET 2022

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us